Lacosamide (Vimpat^®) – a Novel Agent for Add-on Treatment of Focal Epilepsies

Česká verzia

Authors: Doc. MUDr. Jiří Hovorka, CSc.
Authors place of work: Neurologické oddělení, neuropsychiatrické a epileptologické centrum, Nemocnice Na Františku, Praha ¹
Published in the journal: Cesk Slov Neurol N 2011; 74/107(1): 88-95
Category: Novinky v léčbě

Summary

Lacosamide is a new anti-epileptic drug approved in the USA and Europe as adjunctive (add-on) therapy for focal (partial onset) epilepsy in adult patients. Lacosamide has a novel mechanism of action and an excellent pharmacokinetic profile with no clinically relevant drug-drug interactions. The efficacy of lacosamide has been shown in animal models and clinical trials in highly refractory focal epilepsy. Lacosamide is well tolerated. The most common adverse events in recommended doses (up to 400 mg/day) were dizziness, headache and nausea. In this paper, we present a drug profile of lacosamide.

Key words:
epilepsy – treatment of epilepsy – antiepileptic drugs – lacosamide

Zdroje

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked eizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34(3): 453–468.

2. Hovorka J.Farmakologická léčba epilepsie. Cesk Slov Neurol N 2010; 73/106(4): 351–373.

3. Blume WT, Luders HO, Mizrahi E, Tassinari C, van Boas E, Engel J jr. Glossary of descriptive terminology for ital semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001; 42(9): 1212–1218.

4. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46(4): 470–472.

5. Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A et al. Relationship between averse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010; 51(5): 797–804.

6. Beyreuther BK, Freitag J, Heers C, Krebstfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13(1): 21–42.

7. Beydoun A, D’Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurotherapeutics 2009; 9(1): 33–42.

8. Cross SA, Curran MP. Lacosamide in partial-onset seizures. Drugs 2009; 69(4): 449–459.

9. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008; 73(1): 157–169.

10. McCleane G. Lacosamide for pain. Expert Opin Investig Drugs 2010; 19(9): 1129–1134.

11. Bialer M, Johannenssen SI, Kupferberg HJ, Levy RH, Perruca E, Thomson T. Progress report on new antiepileptic druha: a summary of the Eight Eilat Konference (EILAT VIII). Epilepsy Res 2007; 73(1): 1–52.

12. Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Hostmann R. Foot does not affect the pharmacokinetics of SPM 927. Epilepsia 2007; 45 (Suppl 7): 307.

13. Thomas D, Scharfenecker U, Schiltmeyer B. Low potential for drug-drug interaction of lacosamide. Epilepsia 2006; 47 (Suppl 4): 200.

14. Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Bioequivalence of short –time infusions comparet to oral administration of SPM 927. Epilepsia 2004; 45 (Suppl 7): 123–124.

15. Donáth V, Kuchar M, Sýkora P. Epilepsia. Bratislava: Slovenské pedagogické nakladatelstvo 2000.

16. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjuctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48(7): 1308–1317.

17. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomizes controlled trial. Epilepsia 2010; 51(6): 958–967.

18. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, Sullivan T. Adjunctive lacosamide for partial –onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50(3):443–453.

19. Rosenfeld W, Fountain NB, Koubrys G, Heinzen L, McShea C. Lacosamide an interim evaluation of long--term safety an efficacy as oral adjunctive therapy in subjects with partial-onset seizures. Poster, 8th European Epilepsy Congress on Epileptology, 2008, Berlin, Germany.

20. Ben-Menachem E, French JA, Isojarvi J, Hebert D, Daty P. Long term efficacy of lacosamide for partial-onset seizures on interim evaluation of completer cohorts exposed to lacosamide for up to 36 month. Poster, American Epilepsy Society 63rd Annual Meeting 2009, Boston, MA.

21. Sake JK, Hebert D, Isojärvi J, Doty P, De Backer M, Davies K et al. A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs. CNS Drugs 2010; 24(12): 1055–1068.

22. Gil-Nagel A, Biton V, Fountain J, Hebert D, Daty P. The safety and tolerability of lacosamide in randomised, double-blind, placebo-controlled phase II/III clinical trials. Poster, 28th International Epilepsy Congress 2009, Budapešť, Hungary.

23. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaicinie N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49(3): 418–424.